Drug intelligence / Profile preview

123-I MNI-340

Development stage: Phase 1
Lead developer: Institute for Neurodegenerative Disorders
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

123-I MNI-340 is a diagnostic radiopharmaceutical developed as a potential imaging biomarker for β-amyloid burden in the brain. It works as an APP (Beta amyloid A4 protein) inhibitor and is used with Single Photon Emission Computed Tomography (SPECT) imaging. The drug was initially developed to detect beta-amyloid protein deposition in subjects with Alzheimer's disease compared to healthy controls.

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on 123-I MNI-340.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 123-I MNI-340.

Explore the full profile